NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,451 | -2.9% | 44,441 | -6.4% | 0.00% | – |
| Q2 2023 | $27,246 | -12.5% | 47,467 | +9.2% | 0.00% | – |
| Q1 2023 | $31,121 | -66.4% | 43,470 | +5.2% | 0.00% | – |
| Q4 2022 | $92,520 | -37.1% | 41,332 | -9.7% | 0.00% | – |
| Q3 2022 | $147,000 | -15.5% | 45,762 | +0.4% | 0.00% | – |
| Q2 2022 | $174,000 | -95.0% | 45,570 | -1.9% | 0.00% | -100.0% |
| Q1 2022 | $3,457,000 | +664.8% | 46,452 | +39.1% | 0.01% | +600.0% |
| Q4 2021 | $452,000 | -9.2% | 33,389 | +20.6% | 0.00% | 0.0% |
| Q3 2021 | $498,000 | -29.1% | 27,689 | -32.4% | 0.00% | -50.0% |
| Q2 2021 | $702,000 | +3.1% | 40,958 | +20.2% | 0.00% | 0.0% |
| Q1 2021 | $681,000 | +11.5% | 34,061 | -5.2% | 0.00% | 0.0% |
| Q4 2020 | $611,000 | -5.3% | 35,947 | -7.2% | 0.00% | 0.0% |
| Q3 2020 | $645,000 | -19.7% | 38,719 | +11.7% | 0.00% | -33.3% |
| Q2 2020 | $803,000 | -0.7% | 34,674 | -24.9% | 0.00% | 0.0% |
| Q1 2020 | $809,000 | – | 46,195 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |